- Report
- January 2022
- 121 Pages
Global
From €4255EUR$4,750USD£3,627GBP
- Report
- November 2023
- 140 Pages
Global
From €3986EUR$4,450USD£3,398GBP
- Report
- February 2023
- 70 Pages
Global
From €3130EUR$3,495USD£2,669GBP
- Report
- June 2023
- 204 Pages
Global
From €3224EUR$3,600USD£2,749GBP
- Report
- June 2023
- 84 Pages
North America
From €1344EUR$1,500USD£1,145GBP
- Report
- June 2023
- 94 Pages
Middle East, Africa
From €1344EUR$1,500USD£1,145GBP
- Report
- June 2023
- 92 Pages
Asia Pacific
From €1344EUR$1,500USD£1,145GBP
- Report
- June 2023
- 92 Pages
Europe
From €1344EUR$1,500USD£1,145GBP
Opioid Use Disorder (OUD) is a type of addiction disorder that is characterized by the compulsive use of opioids, such as heroin, morphine, and prescription painkillers. OUD is a serious public health issue, with an estimated 2.1 million people in the United States suffering from the disorder. OUD is associated with a range of physical and psychological health problems, including an increased risk of overdose, infectious diseases, and mental health issues. Treatment for OUD typically involves a combination of medication-assisted treatment (MAT) and psychosocial interventions. MAT involves the use of medications, such as buprenorphine and methadone, to reduce cravings and withdrawal symptoms. Psychosocial interventions include cognitive-behavioral therapy, motivational interviewing, and 12-step programs.
Companies in the OUD market include Indivior, Alkermes, Orexo, and Braeburn Pharmaceuticals. Show Less Read more